Aeterna Zentaris Announces Virtual 2023 Meeting of Shareholders
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)…
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS)…
LEXINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid…
LEXINGTON, Mass., May 15, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid…
Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as…
Harish Shantharam, proven leader in building financial organizations to prepare for successful commercialization, appointed as…
Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half…
Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half…
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext & Nasdaq: CYAD) (the…
MONT-SAINT-GUIBERT, Belgium, May 15, 2023 (GLOBE NEWSWIRE) — Celyad Oncology (Euronext & Nasdaq: CYAD) (the…
Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal…
Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal…
Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction…
Recently filed S-4 registration statement for proposed merger with Notable; expects to close the transaction…
– Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with…
– Commenced patient dosing in lorundrostat pivotal clinical program, for the treatment of patients with…
– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company’s share…
– 1Q23 total revenue of $6.2M including collaborative revenue of $2.8M from the Company’s share…
Company has initiated pre-IND discussions with the FDA for its first AIM INJ indication NEXI-001…
Company has initiated pre-IND discussions with the FDA for its first AIM INJ indication NEXI-001…
PHOENIX, May 15, 2023 (GLOBE NEWSWIRE) — MedAvail Holdings, Inc. (NASDAQ: MDVL) (“MedAvail” or the…